share_log

Vertex Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Kewalramani Reshma

SEC announcement ·  May 30 04:14
Summary by Futu AI
Vertex Pharmaceuticals CEO & President, Kewalramani Reshma, completed a stock transaction on 05/24/2024 involving the sale of 1,565 shares of common stock at a price of $457.00 per share. The transaction resulted in a total market value of $715,205. Prior to this sale, Reshma exercised options to acquire the same number of shares at $187.53 per share. Following these transactions, Reshma's direct holdings in Vertex Pharmaceuticals amount to 121,374 shares. The sale took place under the transaction code 'S', indicating an open market or private sale, while the acquisition was coded 'M', signifying the exercise or conversion of derivative security.
Vertex Pharmaceuticals CEO & President, Kewalramani Reshma, completed a stock transaction on 05/24/2024 involving the sale of 1,565 shares of common stock at a price of $457.00 per share. The transaction resulted in a total market value of $715,205. Prior to this sale, Reshma exercised options to acquire the same number of shares at $187.53 per share. Following these transactions, Reshma's direct holdings in Vertex Pharmaceuticals amount to 121,374 shares. The sale took place under the transaction code 'S', indicating an open market or private sale, while the acquisition was coded 'M', signifying the exercise or conversion of derivative security.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.